JP2021517810A - 養子免疫療法における腫瘍自己抗原の使用のための方法および組成物 - Google Patents

養子免疫療法における腫瘍自己抗原の使用のための方法および組成物 Download PDF

Info

Publication number
JP2021517810A
JP2021517810A JP2020548676A JP2020548676A JP2021517810A JP 2021517810 A JP2021517810 A JP 2021517810A JP 2020548676 A JP2020548676 A JP 2020548676A JP 2020548676 A JP2020548676 A JP 2020548676A JP 2021517810 A JP2021517810 A JP 2021517810A
Authority
JP
Japan
Prior art keywords
cells
cancer
cell
tumor
binds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020548676A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021517810A5 (https=
Inventor
ジョン エム． マーリス
ジョン エム． マーリス
マーク ヤルマルコヴィッチ
マーク ヤルマルコヴィッチ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens Hospital of Philadelphia CHOP
Original Assignee
Childrens Hospital of Philadelphia CHOP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hospital of Philadelphia CHOP filed Critical Childrens Hospital of Philadelphia CHOP
Publication of JP2021517810A publication Critical patent/JP2021517810A/ja
Publication of JP2021517810A5 publication Critical patent/JP2021517810A5/ja
Priority to JP2023171939A priority Critical patent/JP7853938B2/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
JP2020548676A 2018-03-12 2019-03-12 養子免疫療法における腫瘍自己抗原の使用のための方法および組成物 Pending JP2021517810A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023171939A JP7853938B2 (ja) 2018-03-12 2023-10-03 養子免疫療法における腫瘍自己抗原の使用のための方法および組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862641541P 2018-03-12 2018-03-12
US62/641,541 2018-03-12
PCT/US2019/021827 WO2019178081A1 (en) 2018-03-12 2019-03-12 Methods and compositions for use of tumor self-antigens in adoptive immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023171939A Division JP7853938B2 (ja) 2018-03-12 2023-10-03 養子免疫療法における腫瘍自己抗原の使用のための方法および組成物

Publications (2)

Publication Number Publication Date
JP2021517810A true JP2021517810A (ja) 2021-07-29
JP2021517810A5 JP2021517810A5 (https=) 2022-03-23

Family

ID=67908079

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020548676A Pending JP2021517810A (ja) 2018-03-12 2019-03-12 養子免疫療法における腫瘍自己抗原の使用のための方法および組成物
JP2023171939A Active JP7853938B2 (ja) 2018-03-12 2023-10-03 養子免疫療法における腫瘍自己抗原の使用のための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023171939A Active JP7853938B2 (ja) 2018-03-12 2023-10-03 養子免疫療法における腫瘍自己抗原の使用のための方法および組成物

Country Status (6)

Country Link
US (1) US12357694B2 (https=)
EP (2) EP4197552A1 (https=)
JP (2) JP2021517810A (https=)
AU (1) AU2019234576B2 (https=)
CA (1) CA3101310A1 (https=)
WO (1) WO2019178081A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013059740A1 (en) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
US11230589B2 (en) 2012-11-05 2022-01-25 Foundation Medicine, Inc. Fusion molecules and uses thereof
US11965892B2 (en) 2017-02-12 2024-04-23 Biontech Us Inc. HLA-based methods and compositions and uses thereof
KR20240091046A (ko) * 2018-12-21 2024-06-21 바이오엔테크 유에스 인크. Hla 클래스 ii-특이적 에피토프 예측 및 cd4+ t 세포 특징화를 위한 방법 및 시스템
EP4359570A4 (en) 2021-06-25 2025-04-30 Foundation Medicine, Inc. METHODS OF USING SOMATIC HLA-I LOH TO PREDICT RESPONSE IN IMMUNE CHECKPOINT INHIBITOR-TREATED PATIENTS WITH LUNG CANCER
CN115636874A (zh) * 2021-07-19 2023-01-24 武汉市朗典精医生物科技有限公司 制备神经肽y（npy）抗体及建立检测npy方法
US20240352130A1 (en) * 2021-08-24 2024-10-24 The Children's Hospital Of Philadelphia Peptide-centric chimeric antigen receptors to cancer self-peptides
EP4399710A2 (en) * 2021-09-10 2024-07-17 Immunoscape Pte. Ltd. Systems and methods for the identification of target-specific t cells and their receptor sequences using machine learning
WO2023235882A2 (en) * 2022-06-03 2023-12-07 Fred Hutchinson Cancer Center Immunotherapy targeting egfr antigens
WO2024178354A2 (en) * 2023-02-24 2024-08-29 The Children's Hospital Of Philadelphia Improved phox2b pc-car generation based on structure and saturation mutagenesis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016102272A1 (en) * 2014-12-23 2016-06-30 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers
WO2017202806A1 (en) * 2016-05-25 2017-11-30 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7109030B2 (en) 2000-03-31 2006-09-19 Nuvelo, Inc. Methods of therapy and diagnosis using insulin-like growth factor binding protein-like polypeptides and polynucleotides
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
AU2003218601A1 (en) 2002-04-08 2003-10-27 The University Of Hong Kong Phox2b polymorphisms as hirschsprung's disease diagnostic markers and methods based thereon
WO2004007770A2 (en) 2002-07-10 2004-01-22 Oncotherapy Science, Inc. Method for diagnosis of intestinal-type gastric tumors
EP1549676A1 (en) 2002-09-30 2005-07-06 Oncotherapy Science, Inc. Genes and polypeptides relating to human myeloid leukemia
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
CN104066746B (zh) * 2011-10-28 2017-12-05 肿瘤疗法科学股份有限公司 Topk肽及包含它们的疫苗
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
US10335471B2 (en) 2015-08-28 2019-07-02 Immatics Biotechnologies Gmbh Method for treating cancer with activated T cells
AU2017254477A1 (en) * 2016-04-18 2018-11-01 Jennifer G. ABELIN Improved HLA epitope prediction
US20180028634A1 (en) 2016-07-29 2018-02-01 Lan Bo Chen Method for prolonging and enhancing anti-tumor vaccine response

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016102272A1 (en) * 2014-12-23 2016-06-30 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers
WO2017202806A1 (en) * 2016-05-25 2017-11-30 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
IMMUNOLOGICAL REVIEWS, vol. 263, no. 1, JPN6023013063, 2015, pages 90 - 105, ISSN: 0005203914 *
NATURE REVIEWS IMMUNOLOGY, vol. 12, no. 4, JPN6023013062, 2012, pages 269 - 281, ISSN: 0005203915 *

Also Published As

Publication number Publication date
US12357694B2 (en) 2025-07-15
WO2019178081A1 (en) 2019-09-19
EP4197552A1 (en) 2023-06-21
JP2024009860A (ja) 2024-01-23
AU2019234576A1 (en) 2020-10-08
EP3765071A4 (en) 2022-05-25
CA3101310A1 (en) 2019-09-19
JP7853938B2 (ja) 2026-04-30
US20210213058A1 (en) 2021-07-15
AU2019234576B2 (en) 2026-02-05
EP3765071A1 (en) 2021-01-20

Similar Documents

Publication Publication Date Title
JP7853938B2 (ja) 養子免疫療法における腫瘍自己抗原の使用のための方法および組成物
US20210138056A1 (en) Neoepitope vaccine compositions and methods of use thereof
KR102081567B1 (ko) 바이오마커 및 종양분해 바이러스 및 면역 조절을 사용한 병용 치료요법
JP2021521776A (ja) Ｍａｇｅ−ｂ２特異性を有するｔ細胞受容体およびその使用
CN113164589A (zh) 用于调节单核细胞和巨噬细胞发炎表型的组合物和方法以及其免疫疗法用途
JP2021502808A (ja) がんの処置におけるｃａｒ−ｔ細胞またはｃａｒ−ｎｋ細胞を用いるｌｉｌｒｂ４のターゲティング法
US20230248814A1 (en) Compositions and methods for treating merkel cell carcinoma (mcc) using hla class i specific epitopes
CN111148518A (zh) 使用cdk4/6抑制剂调控调节性t细胞和免疫应答的方法
KR20220029560A (ko) 신규한 암 항원 및 방법
US20230020894A1 (en) An anaplastic lymphoma kinase (alk) cancer vaccine and methods of use
KR20220070487A (ko) 면역원성 egfr 펩타이드 조성물 및 암의 치료에서 그의 용도
US11564980B2 (en) Tumor treatment method with an individualized peptide vaccine
KR20220034039A (ko) 신규한 암 항원 및 방법
KR20220034040A (ko) 신규한 암 항원 및 방법
KR20220029561A (ko) 신규한 암 항원 및 방법
JP2025515324A (ja) がんを処置するためのキメラ抗原受容体改変調節性ｔ細胞
US20210401887A1 (en) T cells from lymphatic fluid for diagnostic and therapeutic use
JP2023526416A (ja) Ｖｇｌｌ１特異性を有するｔ細胞受容体およびその使用法
KR20220017922A (ko) 면역요법에서의 otub1 표적화
CN120302989A (zh) Magea1免疫原性肽、识别magea1免疫原性肽的结合蛋白和其用途
WO2025096203A1 (en) Targeting a chimeric rna for treating cancer
EP4704864A2 (en) Anaplastic lymphoma kinase (alk) specific t cell receptors and methods of use thereof
WO2023215579A1 (en) Anaplastic lymphoma kinase (alk) cancer vaccines and methods of use thereof
CN118613497A (zh) Magea1免疫原性肽、识别magea1免疫原性肽的结合蛋白和其用途
HK40028190A (en) Methods for modulating regulatory t cells and immune responses using cdk4/6 inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201216

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220314

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220314

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230404

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230630

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230808

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231127